InCrowd – Novel Coronavirus (COVID-19) Vaccine Development

Given the recent uptick in COVID-19 cases in the US, many InCrowd panelists have been reporting that they do not expect things to return to normal until a vaccine is developed and disseminated. In order to deepen our understanding of the COVID-19 vaccine landscape, InCrowd surveyed infectious disease specialists across the country to get their perception and predictions on the efficacy, impact, and competitive landscape of COVID-19 vaccines.

Please note, views in this survey reflect opinions only, as reported by responding physicians.

Methodology:

• Method: 10-minute MicroSurvey via InCrowd
• Crowds: Infectious disease doctors
• Sample Size: n=100
• Fielding Period: June 26th – July 6th

InCrowd’s other COVID-19 Tracking Reports:

• Physician Tracking Report – Wave 6
• Non-Frontline Specialist Tracking Report – Wave 2
• Patient Tracking Report—Wave 3
• Treatment & Outcomes of Diabetes Patients During the COVID-19 Pandemic
• Telemedicine & Remote-Patient Monitoring Report